Karen Bush, PhD - Publications

Affiliations: 
Indiana University, Bloomington, Bloomington, IN, United States 
Area:
Antibiotic resistance, beta-lactamases
Website:
https://biology.indiana.edu/about/faculty/bush-karen.html

159 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Carpenter J, Neidig N, Campbell A, Thornsberry T, Truex T, Fortney T, Zhang Y, Bush K. Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance. The Journal of Antimicrobial Chemotherapy. PMID 31430370 DOI: 10.1093/jac/dkz354  1
2019 Bush K, Bradford PA. Author Correction: Interplay between β-lactamases and new β-lactamase inhibitors. Nature Reviews. Microbiology. PMID 31142821 DOI: 10.1038/s41579-019-0221-6  1
2019 Bush K, Bradford PA. Publisher Correction: Interplay between β-lactamases and new β-lactamase inhibitors. Nature Reviews. Microbiology. PMID 31040389 DOI: 10.1038/s41579-019-0206-5  1
2019 Bush K, Bradford PA. Interplay between β-lactamases and new β-lactamase inhibitors. Nature Reviews. Microbiology. PMID 30837684 DOI: 10.1038/s41579-019-0159-8  1
2018 Bush K. Past and Present Perspectives on β-Lactamases. Antimicrobial Agents and Chemotherapy. PMID 30061284 DOI: 10.1128/AAC.01076-18  0.01
2018 Bush K. Game Changers: New β-Lactamase Inhibitor Combinations Targeting Antibiotic Resistance in Gram-Negative Bacteria. Acs Infectious Diseases. 4: 84-87. PMID 29232103 DOI: 10.1021/acsinfecdis.7b00243  0.01
2017 Zhang Y, Kashikar A, Bush K. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE). The Journal of Antimicrobial Chemotherapy. 72: 2792-2795. PMID 29091224 DOI: 10.1093/jac/dkx261  1
2017 Zhang Y, Kashikar A, Brown CA, Denys G, Bush K. Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam. Antimicrobial Agents and Chemotherapy. 61. PMID 28559260 DOI: 10.1128/AAC.00389-17  1
2017 Jacoby GA, Bush K. Reply to Furlan et al., "Importance of Sequencing To Determine Functional Variants". Antimicrobial Agents and Chemotherapy. 61. PMID 28438798 DOI: 10.1128/AAC.00260-17  1
2016 Jacoby GA, Bush K. The Curious Case of TEM-116. Antimicrobial Agents and Chemotherapy. 60: 7000. PMID 28045664 DOI: 10.1128/AAC.01777-16  1
2016 Kao C, Lin X, Yi G, Zhang Y, Rowe-Magnus DA, Bush K. Cathelicidin Antimicrobial Peptides with Reduced Activation of Toll-Like Receptor Signaling Have Potent Bactericidal Activity against Colistin-Resistant Bacteria. Mbio. 7. PMID 27651360 DOI: 10.1128/mBio.01418-16  1
2016 Zhang Y, Lin X, Bush K. In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. The Journal of Antibiotics. 69: 600-4. PMID 27353166 DOI: 10.1038/ja.2016.73  1
2016 Bush K, Bradford PA. β-Lactams and β-Lactamase Inhibitors: An Overview. Cold Spring Harbor Perspectives in Medicine. 6. PMID 27329032 DOI: 10.1101/cshperspect.a025247  1
2016 Jacoby GA, Bonomo RA, Bradford PA, Bush K, Doi Y, Feldgarden M, Haft D, Klimke W, Nordmann P, Palzkill T, Poirel L, Prasad A, Rossolini GM, Walsh T. Comment on: Resistance gene naming and numbering: is it a new gene or not? The Journal of Antimicrobial Chemotherapy. 71: 2677-8. PMID 27261266 DOI: 10.1093/jac/dkw204  1
2015 Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. International Journal of Antimicrobial Agents. 46: 483-93. PMID 26498989 DOI: 10.1016/j.ijantimicag.2015.08.011  0.01
2015 Li H, Estabrook M, Jacoby GA, Nichols WW, Testa RT, Bush K. In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations. Antimicrobial Agents and Chemotherapy. 59: 1789-93. PMID 25534728 DOI: 10.1128/AAC.04191-14  1
2014 Grant EB, Foleno BD, Goldschmidt R, Hilliard JJ, Lin SC, Morrow B, Paget SD, Weidner-Wells MA, Xu X, Xu X, Murray WV, Bush K, Macielag MJ. 7-(4-Alkylidenylpiperidinyl)-quinolone bacterial topoisomerase inhibitors. Bioorganic & Medicinal Chemistry Letters. 24: 5502-6. PMID 25455493 DOI: 10.1016/j.bmcl.2014.10.014  1
2014 Page MG, Bush K. Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising? Current Opinion in Pharmacology. 18: 91-7. PMID 25277839 DOI: 10.1016/j.coph.2014.09.008  1
2014 Estabrook M, Bussell B, Clugston SL, Bush K. In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases. Journal of Clinical Microbiology. 52: 4049-52. PMID 25143578 DOI: 10.1128/JCM.02357-14  1
2014 Perez F, Arias CA, Bush K, Drusano GL, Lolans K, Munoz-Price LS, Nicolau DP, Queenan AM, Rice LB, Segreti J, Shlaes DM, Weinstein RA, Bonomo RA. In memoriam: John P. Quinn, MD. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 58: 748-50. PMID 24336826 DOI: 10.1093/cid/cit801  1
2013 Bush K. The ABCD's of β-lactamase nomenclature. Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy. 19: 549-59. PMID 23828655 DOI: 10.1007/s10156-013-0640-7  0.01
2013 Hayakawa K, Gattu S, Marchaim D, Bhargava A, Palla M, Alshabani K, Gudur UM, Pulluru H, Bathina P, Sundaragiri PR, Sarkar M, Kakarlapudi H, Ramasamy B, Nanjireddy P, Mohin S, ... ... Bush K, et al. Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. Medical Center. Antimicrobial Agents and Chemotherapy. 57: 4010-8. PMID 23752516 DOI: 10.1128/AAC.02516-12  0.01
2013 Bush K. Proliferation and significance of clinically relevant β-lactamases. Annals of the New York Academy of Sciences. 1277: 84-90. PMID 23346859 DOI: 10.1111/nyas.12023  0.01
2013 Bush K, Pannell M, Lock JL, Queenan AM, Jorgensen JH, Lee RM, Lewis JS, Jarrett D. Detection systems for carbapenemase gene identification should include the SME serine carbapenemase. International Journal of Antimicrobial Agents. 41: 1-4. PMID 23219246 DOI: 10.1016/j.ijantimicag.2012.08.008  1
2011 Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, et al. Tackling antibiotic resistance. Nature Reviews. Microbiology. 9: 894-6. PMID 22048738 DOI: 10.1038/nrmicro2693  1
2011 Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. Annual Review of Microbiology. 65: 455-78. PMID 21740228 DOI: 10.1146/annurev-micro-090110-102911  0.01
2010 Bush K. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Current Opinion in Microbiology. 13: 558-64. PMID 20920882 DOI: 10.1016/j.mib.2010.09.006  0.01
2010 Bush K, Macielag MJ. New β-lactam antibiotics and β-lactamase inhibitors. Expert Opinion On Therapeutic Patents. 20: 1277-93. PMID 20839927 DOI: 10.1517/13543776.2010.515588  0.01
2010 Davies TA, He W, Bush K, Flamm RK. Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin. Antimicrobial Agents and Chemotherapy. 54: 4510-2. PMID 20696872 DOI: 10.1128/AAC.00590-10  1
2010 Queenan AM, Shang W, Bush K, Flamm RK. Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole. Antimicrobial Agents and Chemotherapy. 54: 4092-7. PMID 20606064 DOI: 10.1128/AAC.00060-10  1
2010 Bush K. Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections. Critical Care (London, England). 14: 224. PMID 20594363 DOI: 10.1186/cc8892  0.01
2010 Amsler K, Santoro C, Foleno B, Bush K, Flamm R. Comparison of broth microdilution, agar dilution, and Etest for susceptibility testing of doripenem against gram-negative and gram-positive pathogens. Journal of Clinical Microbiology. 48: 3353-7. PMID 20592149 DOI: 10.1128/JCM.00494-10  1
2010 Louie A, Bied A, Fregeau C, Van Scoy B, Brown D, Liu W, Bush K, Queenan AM, Morrow B, Khashab M, Kahn JB, Nicholson S, Kulawy R, Drusano GL. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrobial Agents and Chemotherapy. 54: 2638-45. PMID 20308371 DOI: 10.1128/AAC.01721-09  1
2010 Roll DM, Yang Y, Wildey MJ, Bush K, Lee MD. Inhibition of metallo-beta-lactamases by pyridine monothiocarboxylic acid analogs. The Journal of Antibiotics. 63: 255-7. PMID 20224603 DOI: 10.1038/ja.2010.20  1
2010 Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, Bush K. In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrobial Agents and Chemotherapy. 54: 1955-64. PMID 20176911 DOI: 10.1128/AAC.01374-09  1
2010 Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrobial Agents and Chemotherapy. 54: 969-76. PMID 19995920 DOI: 10.1128/AAC.01009-09  1
2010 Shang W, Davies TA, Flamm RK, Bush K. Effects of ceftobiprole and oxacillin on mecA expression in methicillin-resistant Staphylococcus aureus clinical isolates. Antimicrobial Agents and Chemotherapy. 54: 956-9. PMID 19949055 DOI: 10.1128/AAC.01024-09  1
2010 Queenan AM, Shang W, Flamm R, Bush K. Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrobial Agents and Chemotherapy. 54: 565-9. PMID 19884379 DOI: 10.1128/AAC.01004-09  1
2010 Fernandez J, Hilliard JJ, Abbanat D, Zhang W, Melton JL, Santoro CM, Flamm RK, Bush K. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 54: 116-25. PMID 19884364 DOI: 10.1128/AAC.00642-09  1
2009 Zhu B, Marinelli BA, Goldschmidt R, Foleno BD, Hilliard JJ, Bush K, Macielag MJ. Synthesis and antibacterial activity of 7-(1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-7-yl) quinolones. Bioorganic & Medicinal Chemistry Letters. 19: 4933-6. PMID 19646867 DOI: 10.1016/j.bmcl.2009.07.087  1
2009 Baum EZ, Crespo-Carbone SM, Foleno BD, Simon LD, Guillemont J, Macielag M, Bush K. MurF inhibitors with antibacterial activity: effect on muropeptide levels. Antimicrobial Agents and Chemotherapy. 53: 3240-7. PMID 19470511 DOI: 10.1128/AAC.00166-09  1
2009 Baum EZ, Crespo-Carbone SM, Morrow BJ, Davies TA, Foleno BD, He W, Queenan AM, Bush K. Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 53: 2785-90. PMID 19433554 DOI: 10.1128/AAC.00018-09  1
2009 Davies TA, Shang W, Amsler KM, Bajaksouzian S, Jacobs MR, Bush K. Molecular characterisation of meticillin-resistant Staphylococcus aureus isolates from two ceftobiprole Phase 3 complicated skin and skin-structure infection clinical trials. International Journal of Antimicrobial Agents. 34: 166-8. PMID 19345071 DOI: 10.1016/j.ijantimicag.2009.02.013  1
2009 Bush K, Jacoby GA, Amicosante G, Bonomo RA, Bradford P, Cornaglia G, Garau J, Giamarellou H, Jarlier V, Martinez-Martinez L, Miriagou V, Palzkill T, Pascual A, Rodriguez-Baño J, Rossolini GM, et al. Comment on: Redefining extended-spectrum beta-lactamases: balancing science and clinical need. The Journal of Antimicrobial Chemotherapy. 64: 212-3; author reply . PMID 19318363 DOI: 10.1093/jac/dkp104  1
2009 Hilliard JJ, Fernandez J, Melton J, Macielag MJ, Goldschmidt R, Bush K, Abbanat D. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. Antimicrobial Agents and Chemotherapy. 53: 2028-33. PMID 19273686 DOI: 10.1128/AAC.00833-08  1
2008 Davies TA, Yee YC, Bush K, Sahm D, Evangelista A, Goldschmidt R. Effects of the 7-valent pneumococcal conjugate vaccine on U.S. levofloxacin-resistant Streptococcus pneumoniae. Microbial Drug Resistance (Larchmont, N.Y.). 14: 187-96. PMID 18707553 DOI: 10.1089/mdr.2008.0805  1
2008 Amsler KM, Davies TA, Shang W, Jacobs MR, Bush K. In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. Antimicrobial Agents and Chemotherapy. 52: 3418-23. PMID 18591277 DOI: 10.1128/AAC.00336-08  1
2008 Davies TA, Shang W, Bush K, Flamm RK. Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 52: 1510-2. PMID 18250190 DOI: 10.1128/AAC.01529-07  1
2008 Davies TA, Shang W, Bush K, Flamm RK. Activity of doripenem and comparator beta-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x. The Journal of Antimicrobial Chemotherapy. 61: 751-3. PMID 18238882 DOI: 10.1093/jac/dkn004  1
2008 Bush K. Extended-spectrum beta-lactamases in North America, 1987-2006. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 14: 134-43. PMID 18154537 DOI: 10.1111/j.1469-0691.2007.01848.x  0.01
2007 Baum EZ, Crespo-Carbone SM, Klinger A, Foleno BD, Turchi I, Macielag M, Bush K. A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli. Antimicrobial Agents and Chemotherapy. 51: 4420-6. PMID 17908943 DOI: 10.1128/AAC.00845-07  1
2007 Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clinical Microbiology Reviews. 20: 440-58, table of con. PMID 17630334 DOI: 10.1128/CMR.00001-07  1
2007 Queenan AM, Shang W, Kania M, Page MG, Bush K. Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. Antimicrobial Agents and Chemotherapy. 51: 3089-95. PMID 17591851 DOI: 10.1128/AAC.00218-07  1
2007 Zhu B, Marinelli BA, Abbanat D, Foleno BD, Bush K, Macielag MJ. Synthesis and antibacterial activity of 3-keto-6-O-carbamoyl-11,12-cyclic thiocarbamate erythromycin A derivatives. Bioorganic & Medicinal Chemistry Letters. 17: 3900-4. PMID 17502142 DOI: 10.1016/j.bmcl.2007.04.104  1
2007 Davies TA, Page MG, Shang W, Andrew T, Kania M, Bush K. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy. 51: 2621-4. PMID 17470659 DOI: 10.1128/AAC.00029-07  1
2007 Bush K, Heep M, Macielag MJ, Noel GJ. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opinion On Investigational Drugs. 16: 419-29. PMID 17371191 DOI: 10.1517/13543784.16.4.419   1
2007 Foleno BD, Abbanat D, Goldschmidt RM, Flamm RK, Paget SD, Webb GC, Wira E, Macielag MJ, Bush K. In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. Antimicrobial Agents and Chemotherapy. 51: 361-5. PMID 17101672 DOI: 10.1128/AAC.01017-06  1
2006 Queenan AM, Shang W, Schreckenberger P, Lolans K, Bush K, Quinn J. SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases. Antimicrobial Agents and Chemotherapy. 50: 3485-7. PMID 17005839 DOI: 10.1128/AAC.00363-06  1
2006 Tennakoon MA, Henninger TC, Abbanat D, Foleno BD, Hilliard JJ, Bush K, Macielag MJ. Synthesis and antibacterial activity of C6-carbazate ketolides. Bioorganic & Medicinal Chemistry Letters. 16: 6231-5. PMID 16997549 DOI: 10.1016/j.bmcl.2006.09.036  1
2006 Fakioglu E, Queenan AM, Bush K, Jenkins SG, Herold BC. Amp C beta-lactamase-producing Escherichia coli in neonatal meningitis: diagnostic and therapeutic challenge. Journal of Perinatology : Official Journal of the California Perinatal Association. 26: 515-7. PMID 16871223 DOI: 10.1038/sj.jp.7211550  1
2006 Paget SD, Boggs CM, Foleno BD, Goldschmidt RM, Hlasta DJ, Weidner-Wells MA, Werblood HM, Bush K, Macielag MJ. Antibacterial activity of pyrrolopyridine-substituted oxazolidinones: synthesis and in vitro SAR of various C-5 acetamide replacements. Bioorganic & Medicinal Chemistry Letters. 16: 4537-42. PMID 16806921 DOI: 10.1016/j.bmcl.2006.06.023  1
2006 Davies TA, Shang W, Bush K. Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrobial Agents and Chemotherapy. 50: 2530-2. PMID 16801437 DOI: 10.1128/AAC.00238-06  1
2006 Grant EB, Guiadeen D, Abbanat D, Foleno BD, Bush K, Macielag MJ. Synthesis and antibacterial activity of 6-O-heteroarylcarbamoyl-11,12-lactoketolides. Bioorganic & Medicinal Chemistry Letters. 16: 1929-33. PMID 16446089 DOI: 10.1016/j.bmcl.2005.12.097  1
2006 Davies TA, Yee YC, Goldschmidt R, Bush K, Sahm DF, Evangelista A. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003). The Journal of Antimicrobial Chemotherapy. 57: 437-42. PMID 16431861 DOI: 10.1093/jac/dki487  1
2006 Baum EZ, Crespo-Carbone SM, Abbanat D, Foleno B, Maden A, Goldschmidt R, Bush K. Utility of muropeptide ligase for identification of inhibitors of the cell wall biosynthesis enzyme MurF. Antimicrobial Agents and Chemotherapy. 50: 230-6. PMID 16377691 DOI: 10.1128/AAC.50.1.230-236.2006  1
2006 Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nature Medicine. 12: 83-8. PMID 16369542 DOI: 10.1038/nm1347  1
2006 Zhu B, Marinelli BA, Abbanat D, Foleno BD, Henninger TC, Bush K, Macielag MJ. Synthesis and antibacterial activity of 3-O-acyl-6-O-carbamoyl erythromycin A derivatives. Bioorganic & Medicinal Chemistry Letters. 16: 1054-9. PMID 16289812 DOI: 10.1016/j.bmcl.2005.10.074  1
2005 Jacoby GA, Bush K. Beta-lactamase nomenclature. Journal of Clinical Microbiology. 43: 6220. PMID 16333139 DOI: 10.1128/JCM.43.12.6220.2005  1
2005 Baum EZ, Crespo-Carbone SM, Foleno B, Peng S, Hilliard JJ, Abbanat D, Goldschmidt R, Bush K. Identification of a dithiazoline inhibitor of Escherichia coli L,D-carboxypeptidase A. Antimicrobial Agents and Chemotherapy. 49: 4500-7. PMID 16251288 DOI: 10.1128/AAC.49.11.4500-4507.2005  1
2005 Lolans K, Queenan AM, Bush K, Sahud A, Quinn JP. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States. Antimicrobial Agents and Chemotherapy. 49: 3538-40. PMID 16048978 DOI: 10.1128/AAC.49.8.3538-3540.2005  1
2005 Davies TA, Bush K, Sahm D, Evangelista A. Predominance of 23S rRNA mutants among non-erm, non-mef macrolide-resistant clinical isolates of Streptococcus pneumoniae collected in the United States in 1999-2000. Antimicrobial Agents and Chemotherapy. 49: 3031-3. PMID 15980393 DOI: 10.1128/AAC.49.7.3031-3033.2005  1
2005 Shaw SJ, Abbanat D, Ashley GW, Bush K, Foleno B, Macielag M, Zhang D, Myles DC. 15-amido erythromycins: synthesis and in vitro activity of a new class of macrolide antibiotics. The Journal of Antibiotics. 58: 167-77. PMID 15895524 DOI: 10.1038/ja.2005.19  1
2005 Frère JM, Galleni M, Bush K, Dideberg O. Is it necessary to change the classification of {beta}-lactamases? The Journal of Antimicrobial Chemotherapy. 55: 1051-3. PMID 15886262 DOI: 10.1093/jac/dki155  1
2005 Xu X, Henninger T, Abbanat D, Bush K, Foleno B, Hilliard J, Macielag M. Synthesis and antibacterial activity of C2-fluoro, C6-carbamate ketolides, and their C9-oximes. Bioorganic & Medicinal Chemistry Letters. 15: 883-7. PMID 15686880 DOI: 10.1016/j.bmcl.2004.12.067  1
2005 Abbanat D, Webb G, Foleno B, Li Y, Macielag M, Montenegro D, Wira E, Bush K. In vitro activities of novel 2-fluoro-naphthyridine-containing ketolides. Antimicrobial Agents and Chemotherapy. 49: 309-15. PMID 15616310 DOI: 10.1128/AAC.49.1.309-315.2005  1
2004 Henninger TC, Xu X, Abbanat D, Baum EZ, Foleno BD, Hilliard JJ, Bush K, Hlasta DJ, Macielag MJ. Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics. Bioorganic & Medicinal Chemistry Letters. 14: 4495-9. PMID 15357979 DOI: 10.1016/j.bmcl.2004.06.045  1
2004 Weidner-Wells MA, Werblood HM, Goldschmidt R, Bush K, Foleno BD, Hilliard JJ, Melton J, Wira E, Macielag MJ. The synthesis and antimicrobial evaluation of a new series of isoxazolinyl oxazolidinones. Bioorganic & Medicinal Chemistry Letters. 14: 3069-72. PMID 15149646 DOI: 10.1016/j.bmcl.2004.04.037  1
2004 Queenan AM, Foleno B, Gownley C, Wira E, Bush K. Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. Journal of Clinical Microbiology. 42: 269-75. PMID 14715764  1
2003 Yigit H, Queenan AM, Rasheed JK, Biddle JW, Domenech-Sanchez A, Alberti S, Bush K, Tenover FC. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2. Antimicrobial Agents and Chemotherapy. 47: 3881-9. PMID 14638498  1
2003 Paget SD, Foleno BD, Boggs CM, Goldschmidt RM, Hlasta DJ, Weidner-Wells MA, Werblood HM, Wira E, Bush K, Macielag MJ. Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones. Bioorganic & Medicinal Chemistry Letters. 13: 4173-7. PMID 14622996  1
2003 Davies TA, Goldschmidt R, Pfleger S, Loeloff M, Bush K, Sahm DF, Evangelista A. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). The Journal of Antimicrobial Chemotherapy. 52: 168-75. PMID 12837740 DOI: 10.1093/jac/dkg309  1
2003 Materon IC, Queenan AM, Koehler TM, Bush K, Palzkill T. Biochemical characterization of beta-lactamases Bla1 and Bla2 from Bacillus anthracis. Antimicrobial Agents and Chemotherapy. 47: 2040-2. PMID 12760895  1
2002 Bush K. The impact of beta-lactamases on the development of novel antimicrobial agents. Current Opinion in Investigational Drugs (London, England : 2000). 3: 1284-90. PMID 12498001  0.01
2002 Granier SA, Leflon-Guibout V, Nicolas-Chanoine MH, Bush K, Goldstein FW. The extended-spectrum K1 beta-lactamase from Klebsiella oxytoca SC 10,436 is a member of the bla(OXY-2) family of chromosomal Klebsiella enzymes. Antimicrobial Agents and Chemotherapy. 46: 2056-7. PMID 12019142 DOI: 10.1128/AAC.46.6.2056-2057.2002  1
2002 Rasheed JK, Anderson GJ, Queenan AM, Biddle JW, Oliver A, Jacoby GA, Bush K, Tenover FC. TEM-71, a novel plasmid-encoded, extended-spectrum beta-lactamase produced by a clinical isolate of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 46: 2000-3. PMID 12019125 DOI: 10.1128/AAC.46.6.2000-2003.2002  1
2002 Docquier JD, Pantanella F, Giuliani F, Thaller MC, Amicosante G, Galleni M, Frère JM, Bush K, Rossolini GM. CAU-1, a subclass B3 metallo-beta-lactamase of low substrate affinity encoded by an ortholog present in the Caulobacter crescentus chromosome. Antimicrobial Agents and Chemotherapy. 46: 1823-30. PMID 12019096  1
2002 Wong-Beringer A, Hindler J, Loeloff M, Queenan AM, Lee N, Pegues DA, Quinn JP, Bush K. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 34: 135-46. PMID 11740699 DOI: 10.1086/324742  1
2001 Queenan AM, Jenkins S, Bush K. Cloning and biochemical characterization of FOX-5, an AmpC-type plasmid-encoded beta-lactamase from a New York City Klebsiella pneumoniae clinical isolate. Antimicrobial Agents and Chemotherapy. 45: 3189-94. PMID 11600376 DOI: 10.1128/AAC.45.11.3189-3194.2001  1
2001 Bush K. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 32: 1085-9. PMID 11264037 DOI: 10.1086/319610  0.01
2001 Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 45: 1151-61. PMID 11257029 DOI: 10.1128/AAC.45.4.1151-1161.2001  1
2000 Urban C, Mariano N, Rahman N, Queenan AM, Montenegro D, Bush K, Rahal JJ. Detection of multiresistant ceftazidime-susceptible Klebsiella pneumoniae isolates lacking TEM-26 after class restriction of cephalosporins. Microbial Drug Resistance (Larchmont, N.Y.). 6: 297-303. PMID 11272258 DOI: 10.1089/mdr.2000.6.297  1
2000 Queenan AM, Torres-Viera C, Gold HS, Carmeli Y, Eliopoulos GM, Moellering RC, Quinn JP, Hindler J, Medeiros AA, Bush K. SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrobial Agents and Chemotherapy. 44: 3035-9. PMID 11036019  1
2000 Grant EB, Guiadeen D, Baum EZ, Foleno BD, Jin H, Montenegro DA, Nelson EA, Bush K, Hlasta DJ. The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors. Bioorganic & Medicinal Chemistry Letters. 10: 2179-82. PMID 11012024 DOI: 10.1016/S0960-894X(00)00444-3  1
1999 Yang Y, Testa RT, Bhachech N, Rasmussen BA, Bush K. Biochemical characterization of novel tetrahydrofuranyl 1beta-methylcarbapenems: stability to hydrolysis by renal dehydropeptidases and bacterial beta-lactamases, binding to penicillin binding proteins, and permeability properties. Antimicrobial Agents and Chemotherapy. 43: 2904-9. PMID 10582880  1
1999 Bush K. beta-Lactamases of increasing clinical importance. Current Pharmaceutical Design. 5: 839-45. PMID 10539991  0.01
1999 Ahmad M, Urban C, Mariano N, Bradford PA, Calcagni E, Projan SJ, Bush K, Rahal JJ. Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 29: 352-5. PMID 10476741 DOI: 10.1086/520214  1
1999 Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, Weinstein RA. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. Jama. 281: 517-23. PMID 10022107  1
1998 Bush K, Mobashery S. How beta-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention. Advances in Experimental Medicine and Biology. 456: 71-98. PMID 10549364  0.01
1998 Bush K, Miller GH. Bacterial enzymatic resistance: beta-lactamases and aminoglycoside-modifying enzymes. Current Opinion in Microbiology. 1: 509-15. PMID 10066532  0.01
1998 Bush K. Metallo-beta-lactamases: a class apart. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 27: S48-53. PMID 9710671  0.01
1998 Yang Y, Bhachech N, Bradford PA, Jett BD, Sahm DF, Bush K. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli isolates producing TEM-10 and TEM-43 beta-lactamases from St. Louis, Missouri. Antimicrobial Agents and Chemotherapy. 42: 1671-6. PMID 9661002  1
1997 Concha NO, Rasmussen BA, Bush K, Herzberg O. Crystal structures of the cadmium- and mercury-substituted metallo-beta-lactamase from Bacteroides fragilis. Protein Science : a Publication of the Protein Society. 6: 2671-6. PMID 9416622 DOI: 10.1002/pro.5560061225  1
1997 Sanders CC, Bradford PA, Ehrhardt AF, Bush K, Young KD, Henderson TA, Sanders WE. Penicillin-binding proteins and induction of AmpC β-lactamase Antimicrobial Agents and Chemotherapy. 41: 2013-2015. PMID 9303404  1
1997 Bush K. The evolution of beta-lactamases. Ciba Foundation Symposium. 207: 152-63; discussion 1. PMID 9189640  0.01
1997 Fung-Tomc J, Bush K, Minassian B, Kolek B, Flamm R, Gradelski E, Bonner D. Antibacterial activity of BMS-180680, a new catechol-containing monobactam. Antimicrobial Agents and Chemotherapy. 41: 1010-6. PMID 9145861  1
1997 Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrobial Agents and Chemotherapy. 41: 563-9. PMID 9055993  1
1997 Bush K, Jacoby G. Nomenclature of TEM beta-lactamases. The Journal of Antimicrobial Chemotherapy. 39: 1-3. PMID 9044020  0.01
1997 Rasmussen BA, Bush K. Carbapenem-hydrolyzing beta-lactamases. Antimicrobial Agents and Chemotherapy. 41: 223-32. PMID 9021171  1
1997 Rasmussen BA, Bush K, Tally FP. Antimicrobial resistance in anaerobes. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 24: S110-20. PMID 8994790  1
1996 Yang Y, Bush K. Biochemical characterization of the carbapenem-hydrolyzing beta-lactamase AsbM1 from Aeromonas sobria AER 14M: a member of a novel subgroup of metallo-beta-lactamases. Fems Microbiology Letters. 137: 193-200. PMID 8998985  1
1996 Rasmussen BA, Bush K, Keeney D, Yang Y, Hare R, O'Gara C, Medeiros AA. Characterization of IMI-1 beta-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrobial Agents and Chemotherapy. 40: 2080-6. PMID 8878585  1
1996 Concha NO, Rasmussen BA, Bush K, Herzberg O. Crystal structure of the wide-spectrum binuclear zinc beta-lactamase from Bacteroides fragilis. Structure (London, England : 1993). 4: 823-36. PMID 8805566 DOI: 10.1016/S0969-2126(96)00089-5  1
1996 Bush K. Is it important to identify extended-spectrum beta-lactamase-producing isolates? European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 15: 361-4. PMID 8793392  0.01
1996 Bradford PA, Jacobus NV, Bhachech N, Bush K. TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum beta-lactamases. Antimicrobial Agents and Chemotherapy. 40: 260-2. PMID 8787920  1
1995 Bradford PA, Urban C, Jaiswal A, Mariano N, Rasmussen BA, Projan SJ, Rahal JJ, Bush K. SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrobial Agents and Chemotherapy. 39: 899-905. PMID 7785992  1
1995 Yang Y, Bhachech N, Bush K. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases. The Journal of Antimicrobial Chemotherapy. 35: 75-84. PMID 7768785  1
1995 Yang Y, Bush K. Oxacillin hydrolysis by the LCR-1 beta-lactamase. Antimicrobial Agents and Chemotherapy. 39: 1209. PMID 7625821  1
1995 Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrobial Agents and Chemotherapy. 39: 1211-33. PMID 7574506  1
1994 Urban C, Meyer KS, Mariano N, Rahal JJ, Flamm R, Rasmussen BA, Bush K. Identification of TEM-26 beta-lactamase responsible for a major outbreak of ceftazidime-resistant Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 38: 392-5. PMID 8192474  1
1994 Bradford PA, Cherubin CE, Idemyor V, Rasmussen BA, Bush K. Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate. Antimicrobial Agents and Chemotherapy. 38: 761-6. PMID 8031043  1
1994 Gonzalez Leiza M, Perez-Diaz JC, Ayala J, Casellas JM, Martinez-Beltran J, Bush K, Baquero F. Gene sequence and biochemical characterization of FOX-1 from Klebsiella pneumoniae, a new AmpC-type plasmid-mediated beta-lactamase with two molecular variants. Antimicrobial Agents and Chemotherapy. 38: 2150-7. PMID 7811034  0.01
1994 Rasmussen BA, Yang Y, Jacobus N, Bush K. Contribution of enzymatic properties, cell permeability, and enzyme expression to microbiological activities of beta-lactams in three Bacteroides fragilis isolates that harbor a metallo-beta-lactamase gene. Antimicrobial Agents and Chemotherapy. 38: 2116-20. PMID 7811029  1
1994 Rasmussen BA, Keeney D, Yang Y, Bush K. Cloning and expression of a cloxacillin-hydrolyzing enzyme and a cephalosporinase from Aeromonas sobria AER 14M in Escherichia coli: requirement for an E. coli chromosomal mutation for efficient expression of the class D enzyme. Antimicrobial Agents and Chemotherapy. 38: 2078-85. PMID 7811022  1
1993 Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. Kinetic interactions of tazobactam with β-lactamases from all major structural classes Antimicrobial Agents and Chemotherapy. 37: 851-858. PMID 8388201  1
1993 Rasmussen BA, Bush K, Tally FP. Antimicrobial resistance in Bacteroides. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 16: S390-400. PMID 8324154  1
1993 Rasmussen BA, Bradford PA, Quinn JP, Wiener J, Weinstein RA, Bush K. Genetically diverse ceftazidime-resistant isolates from a single center: biochemical and genetic characterization of TEM-10 beta-lactamases encoded by different nucleotide sequences. Antimicrobial Agents and Chemotherapy. 37: 1989-92. PMID 8239618  1
1992 Yang Y, Rasmussen BA, Bush K. Biochemical characterization of the metallo-beta-lactamase CcrA from Bacteroides fragilis TAL3636. Antimicrobial Agents and Chemotherapy. 36: 1155-7. PMID 1510410  1
1992 Naumovski L, Quinn JP, Miyashiro D, Patel M, Bush K, Singer SB, Graves D, Palzkill T, Arvin AM. Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrobial Agents and Chemotherapy. 36: 1991-6. PMID 1416892  1
1991 Sowek JA, Singer SB, Ohringer S, Malley MF, Dougherty TJ, Gougoutas JZ, Bush K. Substitution of lysine at position 104 or 240 of TEM-1pTZ18R beta-lactamase enhances the effect of serine-164 substitution on hydrolysis or affinity for cephalosporins and the monobactam aztreonam. Biochemistry. 30: 3179-88. PMID 1901218  1
1991 Bush K, Flamm RK, Ohringer S, Singer SB, Summerill R, Bonner DP. Effect of clavulanic acid on activity of beta-lactam antibiotics in Serratia marcescens isolates producing both a TEM beta-lactamase and a chromosomal cephalosporinase. Antimicrobial Agents and Chemotherapy. 35: 2203-8. PMID 1803992  1
1989 Bush K, Singer SB. Effective cooling allows sonication to be used for liberation of beta-lactamases from gram negative bacteria. The Journal of Antimicrobial Chemotherapy. 24: 82-4. PMID 2789212  1
1989 Bush K. Excitement in the beta-lactamase arena. The Journal of Antimicrobial Chemotherapy. 24: 831-6. PMID 2695508  0.01
1989 Quinn JP, Miyashiro D, Sahm D, Flamm R, Bush K. Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 33: 1451-6. PMID 2684007  1
1989 Bush K. Classification of beta-lactamases: groups 2c, 2d, 2e, 3, and 4. Antimicrobial Agents and Chemotherapy. 33: 271-6. PMID 2658781  0.01
1989 Bush K. Classification of beta-lactamases: groups 1, 2a, 2b, and 2b'. Antimicrobial Agents and Chemotherapy. 33: 264-70. PMID 2658780  0.01
1989 Bush K. Characterization of beta-lactamases. Antimicrobial Agents and Chemotherapy. 33: 259-63. PMID 2658779  0.01
1989 Bush K, Singer SB. Biochemical characteristics of extended broad spectrum beta-lactamases. Infection. 17: 429-33. PMID 2613337  1
1988 Bush K, Smith SA, Tanaka SK, Bonner DP. Inactivation of beta-lactamases from Enterobacter cloacae by monophosphams. The Journal of Antimicrobial Chemotherapy. 22: 801-9. PMID 3266620 DOI: 10.1093/jac/22.6.801  1
1988 Bush K. Beta-lactamase inhibitors from laboratory to clinic. Clinical Microbiology Reviews. 1: 109-23. PMID 3060240  0.01
1988 Bush K. Recent developments in beta-lactamase research and their implications for the future. Reviews of Infectious Diseases. 10: 681-90. PMID 3055169  0.01
1987 Bush K, Smith SA, Ohringer S, Tanaka SK, Bonner DP. Improved sensitivity in assays for binding of novel beta-lactam antibiotics to penicillin-binding proteins of Escherichia coli. Antimicrobial Agents and Chemotherapy. 31: 1271-3. PMID 3307621  1
1987 Tanaka SK, Summerill RA, Minassian BF, Bush K, Visnic DA, Bonner DP, Sykes RB. In vitro evaluation of tigemonam, a novel oral monobactam. Antimicrobial Agents and Chemotherapy. 31: 219-25. PMID 3105448  1
1986 Joris B, De Meester F, Galleni M, Masson S, Dusart J, Frère JM, Van Beeumen J, Bush K, Sykes R. Properties of a class C beta-lactamase from Serratia marcescens. The Biochemical Journal. 239: 581-6. PMID 3548700  1
1986 Bush K, Sykes RB. Methodology for the study of beta-lactamases. Antimicrobial Agents and Chemotherapy. 30: 6-10. PMID 3530125  0.01
1985 Bush K, Tanaka SK, Bonner DP, Sykes RB. Resistance caused by decreased penetration of beta-lactam antibiotics into Enterobacter cloacae. Antimicrobial Agents and Chemotherapy. 27: 555-60. PMID 3873900  1
1983 Cooper R, Bush K, Principe PA, Trejo WH, Wells JS, Sykes RB. Two new monobactam antibiotics produced by a Flexibacter sp. I. Taxonomy, fermentation, isolation and biological properties. The Journal of Antibiotics. 36: 1252-7. PMID 6643274  1
1983 Bush K, Sykes RB. beta-Lactamase inhibitors in perspective. The Journal of Antimicrobial Chemotherapy. 11: 97-107. PMID 6339464  1
1982 Bush K, Freudenberger JS, Slusarchyk DS, Sykes RB, Meyers E. Activity of sulfa drugs and dihydrofolate reductase inhibitors against Candida albicans. Experientia. 38: 436-7. PMID 7044814  1
1982 Bush K, Freudenberger JS, Sykes RB. Interaction of azthreonam and related monobactams with beta-lactamases from gram-negative bacteria. Antimicrobial Agents and Chemotherapy. 22: 414-20. PMID 6982680  1
1982 Sykes RB, Bonner DP, Bush K, Georgopapadakou NH. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrobial Agents and Chemotherapy. 21: 85-92. PMID 6979307  1
1982 Wells JS, Trejo WH, Principe PA, Bush K, Georgopapadakou N, Bonner DP, Sykes RB. EM5400, a family of monobactam antibiotics produced by Agrobacterium radiobacter. I. Taxonomy, fermentation and biological properties. The Journal of Antibiotics. 35: 295-9. PMID 6978878  1
1982 Wells JS, Trejo WH, Principe PA, Bush K, Georgopapadakou N, Bonner DP, Sykes RB. SQ 26,180, a novel monobactam. I Taxonomy, fermentation and biological properties. The Journal of Antibiotics. 35: 184-8. PMID 6978877  1
1981 Sykes RB, Cimarusti CM, Bonner DP, Bush K, Floyd DM, Georgopapadakou NH, Koster WM, Liu WC, Parker WL, Principe PA, Rathnum ML, Slusarchyk WA, Trejo WH, Wells JS. Monocyclic beta-lactam antibiotics produced by bacteria. Nature. 291: 489-91. PMID 7015152 DOI: 10.1038/291489a0  1
1981 Sykes RB, Bonner DP, Bush K, Georgopapadakou NH, Wells JS. Monobactams--monocyclic beta-lactam antibiotics produced by bacteria. The Journal of Antimicrobial Chemotherapy. 8: 1-16. PMID 6976959  1
1980 Bush K, Freudenberger J, Sykes RB. Inhibition of Escherichia coli TEM-2 beta-lactamase by the sulfated compounds izumenolide, panosialin and sodium dodecyl sulfate. The Journal of Antibiotics. 33: 1560-2. PMID 7019178  1
1980 Bush K, Bonner DP, Sykes RB. Izumenolide-a novel beta-lactamase inhibitor produced by Micromonospora. II. Biological properties. The Journal of Antibiotics. 33: 1262-9. PMID 6972939  1
1973 Bush K, Shiner VJ, Mahler HR. Deuterium isotope effects on initial rates of the liver alcohol dehydrogenase reaction. Biochemistry. 12: 4802-5. PMID 4359375  1
1972 Bush KJ, Sweeney BM. The Activity of Ribulose Diphosphate Carboxylase in Extracts of Gonyaulax polyedra in the Day and the Night Phases of the Circadian Rhythm of Photosynthesis. Plant Physiology. 50: 446-51. PMID 16658193  1
1971 Bush K, Mahler HR, Shiner VJ. Deuterium effects on binding of reduced coenzyme alcohol dehydrogenase isoenzyme EE. Science (New York, N.Y.). 172: 478-80. PMID 4323799  1
Show low-probability matches.